Curative Biotechnology Inc (CUBT)

[conix]

The question is not what the price per share would be if Metformin eye drop formulation was proven effective and eventually sold to a Big Pharma. A number of steps will happen before that -- like an announced partnership with investment into the company--that will have an effect on the market capitalization of the company.

An effective therapy for AMD through direct delivery to the eye with no need of injections into the eye would be worth well over $2 Billion, imo. Depending upon how many shares there are outstanding at the time--regardless of a RS or not--it would be substantially higher than the current market cap even accounting for a capital raise.

In a perfect world, the company would be flush with cash and already on NASDAQ. Judging by the filings and charts, three years ago, this ticker symbol was worth basically nothing with no business plan or future.

jmo